NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
2025-06-30 | 2025-03-31 | 2024-06-30 | ||
|---|---|---|---|---|
| Product revenue | 1,696,050 | 1,386,550 | 825,776 | |
| Cost of product revenue | 781,215 | 615,489 | 543,904 | |
| Product gross profit | 914,835 | 771,061 | 281,872 | |
| License revenue | - | - | - | |
| Selling, general and administrative | 1,618,950 | 1,940,414 | 1,881,099 | |
| Research and development | 1,182,485 | 1,510,663 | 1,194,674 | |
| Total operating expenses | 2,801,435 | 3,451,077 | 3,075,773 | |
| Loss from operations | -1,886,600 | -2,680,016 | -2,793,901 | |
| Fair value change in warrant liability | -319,625 | -390,351 | - | |
| Financing costs | 9,325 | - | - | |
| Other income | 75,432 | - | - | |
| Other income, net | - | 19,058 | 26,376 | |
| Loss before income taxes | -1,500,868 | -2,270,607 | -2,767,525 | |
| Provision for income taxes | - | - | - | |
| Net loss | -1,500,868 | -2,270,607 | -2,767,525 | |
| Basic (in dollars per share) | -0.03 | -0.07 | -0.1 | |
| Basic (in shares) | 48,604,996 | 31,111,786 | 27,352,660 | |
| Diluted (in dollars per share) | -0.03 | -0.07 | -0.1 | |
| Diluted (in shares) | 48,604,996 | 31,111,786 | 27,352,660 | |